CNSP CNS Pharmaceuticals, Inc.: institutional ownership and insider trading
11 funds reported holding $1.34M of CNS Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net bought $645K, with 4 new positions and 4 funds selling out; over the last 12 months insiders bought $44.0K and sold $0 on the open market.
CNSP revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.59M, EPS -0.38
- Quarter ended Mar 31, 2026: revenue n/a, net income −$4.94M, EPS -7.30
- Quarter ended Dec 31, 2025: revenue n/a, net income $9.88M, EPS -4.64
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.22M, EPS -5.76
Largest institutional holders of CNSP
- Ikarian Capital, LLC — $649K
- ADAR1 Capital Management, LLC — $335K
- Stonepine Capital Management, LLC — $199K
- BOOTHBAY FUND MANAGEMENT, LLC — $64.6K
- VANGUARD FIDUCIARY TRUST CO — $48.9K
- VANGUARD CAPITAL MANAGEMENT LLC — $33.4K
- UBS Group AG (UBS) — $6.98K
- Tower Research Capital LLC (TRC) — $3.82K
- BARCLAYS PLC (BCS, BCLYF) — $91
- BARRETT & COMPANY, INC. — $42
Recent CNSP insider trades
- May 18, 2026: Fisher Michal bought 2,000 shares ($10.0K)
- May 18, 2026: Charles Faith L. bought 7,100 shares ($34.0K)
5%+ owners
- Ikarian Capital, LLC: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- Stonepine Capital Management, LLC: 9.9% (Schedule 13G/A, filed May 15, 2026)
Who owns the most CNSP stock?
The largest institutional holders of CNS Pharmaceuticals, Inc. in the latest 13F filings are Ikarian Capital, LLC ($649K), ADAR1 Capital Management, LLC ($335K), Stonepine Capital Management, LLC ($199K).
Are insiders buying or selling CNSP?
Over the last 12 months insiders bought $44.0K and sold $0 of CNS Pharmaceuticals, Inc. stock on the open market (SEC Form 4).